Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy
Aim: Accurate causality assessment (CA) of adverse events (AEs) is important in clinical research and routine clinical practice. The Naranjo scale (NS) used for CA lacks specificity, leading to a high rate of false positive causal associations. NS is a simple scale for CA; however, its limitations h...
Saved in:
Main Authors: | Jyoti Bhagatram Sharma (Author), Manjunath Nookala Krishnamurthy (Author), Ankita Awase (Author), Amit Joshi (Author), Vijay Patil (Author), Vanita Noronha (Author), Kumar Prabhash (Author), Vikram Gota (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
by: Zhong AY, et al.
Published: (2015) -
Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024) -
Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
by: Yangchun Gu, et al.
Published: (2021) -
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
by: Hope Cottrill MD, et al.
Published: (2018) -
Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
by: Seiji Isonishi, et al.
Published: (2022)